Shots: The P-III study involves assessing of spartalizumab (PDR001) + Tafinlar (dabrafenib) and Mekinist (trametinib) vs PBO + Tafinlar and Mekinist in previously untreated patients with unresectable or metastatic BRAF […]readmore
Tags : Triple Regimen
Shots: The P-III ELOQUENT-1 study involves assessing of Empliciti (elotuzumab)+ Revlimid (lenalidomide) and dexamethasone (ERd) vs Rd in transplant-ineligible patients with newly diagnosed, previously untreated MM The P-III ELOQUENT-1 study […]readmore
Shots: The US FDA has approved Trijardy XR which includes Jardiance (empagliflozin), Tradjenta (linagliptin) and metformin hydrochloride extended-release to lower blood sugar in adults with T2D, along with diet and […]readmore
Regulatory
BMS’s Triple Regimen Receives European Commission Approval for Relapse/Refractory Multiple
Shots: The approval is based on P-II ELOQUENT-3 study assessing Empliciti (elotuzumab) + pomalidomide and low-dose dexamethasone (EPd) vs pomalidomide and low-dose dexamethasone (Pd) in 117 patients with r/r MM […]readmore
Shots: The opinion is based on P-II ELOQUENT-3 study assessing Empliciti (elotuzumab) + pomalidomide and dexamethasone (EPd) vs pomalidomide + dexamethasone (Pd) in 117 patients in a ratio (1:1) with […]readmore
Regulatory
Celgene’s Pomalyst (pomalidomide)-Based Triple Regimen Receive Health Canada’s Approval for
Shots: The approval is based on P-III OPTIMISMM study results assessing Pomalyst + bortezomib and dexamethasone vs bortezomib + dexamethasone in 559 patients in a ratio (1:1) with 2L+ MM […]readmore